Sinovac Biotech, Ltd.
-
Ticker
SVA
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 501-1000 Employees
- Based in Beijing, China
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac’s product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, Quadrivalent Influenza vaccine (“QIV”), H5N1 pandemic influenza (avian
…More flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government’s vaccination campaign and stockpiling program.
Sinovac Biotech, Ltd.
Most Recent Responsibility Report
MOST RECENT
2022 Corporate Social Responsibility Report
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived Sinovac Biotech, Ltd. Sustainability Report, Sinovac Biotech, Ltd. Corporate Social Responsibility Report, Sinovac Biotech, Ltd. CSR Report, Sinovac Biotech, Ltd. Corporate Responsibility, Sinovac Biotech, Ltd. CR Report, Sinovac Biotech, Ltd. Citizenship Report, Sinovac Biotech, Ltd. ESG Report, and Sinovac Biotech, Ltd. Environmental Report online.